SD
Suk See De Ravin
Research areas: Immunology and Microbiology · Immunology · Immunodeficiency and Autoimmune Disorders · Virus-based gene therapy research · CRISPR and Genetic Engineering
0000-0002-9800-774X
Employment
Employment history is unavailable.
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (76)
- Poor T-cell receptor β repertoire diversity early posttransplant for severe combined immunodeficiency predicts failure of immune reconstitution. Save
- CRISPR-targeted MAGT1 insertion restores XMEN patient hematopoietic stem cells and lymphocytes. Save
- Long-term Outcomes after Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency (ADA SCID). Save
- Enhanced homology-directed repair for highly efficient gene editing in hematopoietic stem/progenitor cells. Save
- Immunodeficiency and bone marrow failure with mosaic and germline TLR8 gain of function. Save
- Preclinical evaluation for engraftment of CD34+ cells gene-edited at the sickle cell disease locus in xenograft mouse and non-human primate models. Save
- Safety and Efficacy of Ustekinumab in the Inflammatory Bowel Disease of Chronic Granulomatous Disease. Save
- Correction of X-CGD patient HSPCs by targeted CYBB cDNA insertion using CRISPR/Cas9 with 53BP1 inhibition for enhanced homology-directed repair. Save
- Gene Editing Rescues In vitro T Cell Development of RAG2-Deficient Induced Pluripotent Stem Cells in an Artificial Thymic Organoid System. Save
- NADPH oxidase correction by mRNA transfection of apheresis granulocytes in chronic granulomatous disease. Save
- MAGT1 messenger RNA-corrected autologous T and natural killer cells for potential cell therapy in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia disease. Save
- Progressive B Cell Loss in Revertant X-SCID. Save
- Artificial thymic organoids represent a reliable tool to study T-cell differentiation in patients with severe T-cell lymphopenia. Save
- The response to vedolizumab in chronic granulomatous disease-related inflammatory bowel disease. Save
- Lentiviral gene therapy for X-linked chronic granulomatous disease. Save
- Defective glycosylation and multisystem abnormalities characterize the primary immunodeficiency XMEN disease. Save
- CRISPR/Cas9 applications in gene therapy for primary immunodeficiency diseases. Save
- Aberrant Clonal Hematopoiesis following Lentiviral Vector Transduction of HSPCs in a Rhesus Macaque. Save
- Gene correction for SCID-X1 in long-term hematopoietic stem cells. Save
- Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1. Save